Foley Hospital Company LLC
Foley Hospital Company LLC was paid $4.48M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
FOLEY, AL 36535
Next to other Ambulatory Surgical Clinic/Center providers in Alabama
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,135 | $306K | |
| 2019 | 17,980 | $424K | |
| 2020 | 19,173 | $481K | |
| 2021 | 24,617 | $677K | |
| 2022 | 28,314 | $890K | |
| 2023 | 29,431 | $1.06M | |
| 2024incomplete | 16,981 | $638K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 29,091 | 25,236 | $1.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 18,811 | 15,877 | $1.29M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 9.7% | 9,938 | 9,199 | $435K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.0% | 10,896 | 10,049 | $269K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 880 | 719 | $175K |
| 80053 | Comprehensive metabolic panel | 3.2% | 14,579 | 11,953 | $141K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.9% | 8,032 | 7,382 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 16,451 | 13,381 | $122K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.1% | 5,477 | 5,242 | $93K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 1,965 | 1,773 | $91K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 703 | 620 | $58K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,349 | 1,178 | $53K |
56 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 1,085 | $47K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,423 | $36K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,467 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,933 | $29K |
| 81001 | <1% | 7,823 | $26K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 179 | $26K |
| 84703 | <1% | 3,118 | $18K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 600 | $13K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,037 | $11K |
| 87807 | <1% | 752 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 699 | $8K |
| 83690 | <1% | 1,007 | $7K | |
| 84484 | <1% | 899 | $6K | |
| 82553 | <1% | 559 | $5K | |
| 82550 | <1% | 953 | $5K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,048 | $5K |
| 81003 | <1% | 1,424 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 37 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 347 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 69 | $3K |
| 83735 | <1% | 345 | $2K | |
| 83704 | <1% | 95 | $2K | |
| 85610 | <1% | 391 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 128 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18 | $1K |
| 82172 | <1% | 95 | $1K | |
| 80061 | Lipid panel | <1% | 109 | $1K |
| 85027 | <1% | 224 | $1K | |
| 85007 | <1% | 211 | $862.65 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $673.44 |
| 83695 | <1% | 95 | $671.60 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 744 | $631.85 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,276 | $571.93 |
| 82247 | <1% | 190 | $541.30 | |
| 85730 | <1% | 192 | $369.05 | |
| 85651 | <1% | 133 | $365.40 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 57 | $205.69 |
| 73630 | <1% | 13 | $200.10 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 73 | $170.61 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $169.68 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $161.76 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12 | $131.37 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 60 | $95.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 36 | $66.77 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19 | $52.16 |
| 86900 | <1% | 16 | $29.61 | |
| 86901 | <1% | 16 | $29.34 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 42 | $27.72 |
| 86140 | <1% | 12 | $24.42 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 67 | $10.59 |
| 87077 | 0% | 38 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 147 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 39 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.